

SunWay Biotech Co., LTD.

United States, Canada, European Union, Japan, Singapore, South Korea, China, Taiwan patents

ANKASEIN® 568-R with Monascus purpureus NTU 568 **Red yeast extract**

Free of Statins' Risks; **Better than Statins' Benefits!**

- Free of all statins (monacolin K)
- New Dietary Ingredient (NDI) status approved by the FDA
- More-than-ten-year research by the National Taiwan University research team
- More than 120 research publications including in vitro and in vivo experiments to prove its benefits and safety
- Health benefits supported by randomized controlled clinical trials
- Patent Monascus strain (NTU 568)
- New active compounds: monascin (MS) and ankaflavin (AK)
- No side effects
- Exclusive automated solid-state fermentation technology
- Multi-national patents
- GMO free, no major food allergens
- HACCP, ISO 22000 certification








Beneficial Effects of ANKASCIN® 568-R

Blood Lipids

Better anti-atherosclerosis effects of monascin & akaflavin (active compounds in ANKASCIN 568-R) on hamsters fed with a high cholesterol diet, compared with monacolin K (lovastatin)




LDL-C

Journal of Agricultural and Food Chemistry 2013, 61,143-150

Clinical Trial

After 8 weeks of administration, cholesterol and LDL-C were significantly reduced by 11.1% and 20.4%




210 -20.4% 180 150 120 mg/dL 90 60 30 0 Week 0 Week 4 Week 8 Week 12


Administration

Blood Glucose

Monascin maintained insulin expression levels against methylglyoxal-induced damage to pancreatic tissues




Control



Monascin

Insulin expression




Methylglyoxal injection



Rosiglitazone (diabetic drug)



Fasting Blood Glucose




Journal of Food and Drug Analysis (2016) online

Journal of Agricultural and Food Chemistry 2013, 61, 5996-6006


Blood Pressure

Blood pressure was reduced in the short term and maintained in the long term in SHR rats



SHR: spontaneously hypertensive rats; SBP: systolic blood pressure; DBP: diastolic blood pressure

ANKASCIN 568-R made elastin fibers straighter and easier to manage blood pressure change



100 µm

Hypertensive A

Irregular elastin fibers

100 µm

ANKASCIN 568-R

Dementia and Alzheimer's Disease

Alzheimer's Disease (AD) is a progressive neurodegenerative disease characterized by the abnormal secretion and accumulation of amyloid β fibrils which are associated with neurotoxicity in the brain hippocampus. Amyloid β aggregation can contribute to neuronal cell death and further loss of memory and dementia.

Memory and	Improvement	
Learning Ability	MS	AK
Reference memory task	35.8%	30.0%
Probe test	30.2%	25.3%
Working memory task	69.1%	70.9%

Journal of Functional Foods. 18 (2015) 387-399

Amyloid Precusor Protein (APP) for AD was significantly reduced in hippocampus



APP expression in immunohistochemistry stain








Control

Treated with aluminum


ANKASCIN 568-R



induced by the high chergy diet

Key risk factors (Αβ₁₋₄₂, Αβ₁₋₄₀, pTau) for AD were significantly reduced in hippocampus

C: normal diet; A: treated with aluminum; R: ANKASCIN 568-R



Patents

Title	Patent
Composition and method for prevention and treatment of Alzheimer's Disease	Korea (2010.05), Singapore (2010.10), Taiwan (2011.05), Japan (2012.04) Australia (2013.06), Taiwan (2013.09), European Union (Germany, France, United Kingdom, Switzerland, Ireland, Netherlands, Sweden, Austria, Belgium, Italy, Portugal, Spain, and Turkey) (2016.03)
A composition comprising an extract of red mold rice for treatment of Alzheimer's Disease	Canada (2012.11)
A method for manufacturing a composition comprising an extract of red mold rice for treatment of Alzheimer's Disease	Canada (2016.02)
Method for prevention and treatment of Alzheimer's Disease	U.S.A (2012.01)
Manufacturing process of red mold Dioscorea	Taiwan (2011.10), Japan (2012.03), Korea (2013.01), China (2013.09), U.S.A (2014.04), U.S.A (2014.04)
Composition of <i>Monascus</i> fermented product with a function that reduces body fatness formation and the method of manufacturing the same	China (2012.09)
Composition for lowering blood lipid and elevating high density lipoprotein and method for manufacturing the same	Taiwan (2013.11), Korea (2014.07), European Union (Germany, France, United Kingdom, Switzerland, Netherlands, and Italy) (2014.11), Singapore (2015.07), Canada (2015.10), Japan (2016.04), Canada (2016.04), Canada (2016.04), China (2016.05), U.S.A (2016.06), U.S.A (2016.06)



Scientifically Proven Health Benefits



Safety

- 90-Day Repeated Dose Oral Toxicity Test
- Salmonella Reverse Mutation Test
- In vitro Mammalian Chromosomal Aberration Test
- Rodent Micronucleus Test in Peripheral Blood
- New Dietary Ingredient (NDI) Status Approved by the FDA

Specification

Applicable Formulation: Sachets, Tablets, and Capsules

Raw material	Specification of active ingredient	Aspect	Dosage
ANKASCIN 568-R	Monascin \ge 28 mg/g Ankaflavin \ge 9 mg/g	Powder	Blood lipids: 110 mg/day Blood glucose: 220 mg/day Blood pressure: 220 mg/day Memory & cognitive health: 220 mg/day

SunWay Biotech Co., LTD. www.sunway.cc / globalservice@sunway.cc